# FDA Rejected MDMA for PTSD. Now It Wants the Sequel to Succeed. - Date: 2026-04-24 - Category: Biotech & Life Sciences A methylone pill for PTSD showed a 9.64-point improvement over placebo in Phase 2 — and the FDA just fast-tracked it with a priority review voucher, after rejecting the last psychedelic PTSD drug in 2024 for trial design flaws. ---